Aerpio Pharmaceuticals is a pharmaceutical company spun out of Akebia Therapeutics, with programs focused on Tie2 activation for the treatment of retinopathy, vascular leak, cancer, inflammatory bowel disease and would healing.
Aerpio Pharmaceuticals Presents Analysis from TIME-2 Study Regarding Effects of AKB-9778 on Renal Function at 2018 Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ Injury
Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy
Aerpio Pharmaceuticals Announces Appointment of Michael Rogers as Chief Financial Officer
